Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
04 07 2022
Historique:
pubmed: 12 1 2022
medline: 7 7 2022
entrez: 11 1 2022
Statut: epublish

Résumé

While ovarian cancer is the third most common Lynch syndrome-associated cancer in women, there is no established screening strategy to identify Lynch syndrome in this population. The objective of this study was to assess whether the 4-item brief Family History Questionnaire can be used as a screening tool to identify women with ovarian cancer at risk of Lynch syndrome. In this prospective cohort study, participants with newly diagnosed non-serous, non-mucinous ovarian cancer completed the brief Family History Questionnaire, extended Family History Questionnaire, and had tumors assessed with immunohistochemistry for mismatch repair proteins, Of 215 participants, 169 (79%) were evaluable with both the brief Family History Questionnaire and germline mutation status; 12 of these 169 were confirmed to have Lynch syndrome (7%). 10 of 12 patients (83%) with Lynch syndrome were correctly identified by the brief Family History Questionnaire, compared with 6 of 11 (55%) by the extended Family History Questionnaire, 11 of 13 (85%) by immunohistochemistry± The brief Family History Questionnaire alone or combined with immunohistochemistry may serve as an adequate screening strategy, especially in centers without access to universal tumor testing.

Identifiants

pubmed: 35012974
pii: ijgc-2021-003082
doi: 10.1136/ijgc-2021-003082
doi:

Substances chimiques

MutL Protein Homolog 1 EC 3.6.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

891-898

Informations de copyright

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Soyoun Rachel Kim (SR)

Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada rachelkim89@gmail.com eiriksson@HHSC.CA.
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.

Alicia Tone (A)

Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada.

Raymond Kim (R)

Fred A Litwin Family Centre for Genetic Medicine, University Health Network, Toronto, Ontario, Canada.
Zane Cohen Centre for Digestive Diseases, Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, Ontario, Canada.
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada.

Matthew Cesari (M)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Blaise Clarke (B)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Tae Hart (T)

Department of Psychology, Ryerson University, Toronto, Ontario, Canada.

Melyssa Aronson (M)

Zane Cohen Centre for Digestive Diseases, Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, Ontario, Canada.

Spring Holter (S)

Zane Cohen Centre for Digestive Diseases, Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, Ontario, Canada.

Alice Lytwyn (A)

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

Manjula Maganti (M)

Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Leslie Oldfield (L)

Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Steven Gallinger (S)

Division of General Surgery, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada.

Marcus Q Bernardini (MQ)

Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada.
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.

Amit M Oza (AM)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada.

Bojana Djordjevic (B)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Jordan Lerner-Ellis (J)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Emily Van de Laar (E)

Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada.

Danielle Vicus (D)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Trevor J Pugh (TJ)

Ontario Institute for Cancer Research, University Health Network, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Aaron Pollett (A)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Sarah Elizabeth Ferguson (SE)

Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Sinai Health Systems, Toronto, Ontario, Canada.
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.

Lua Eiriksson (L)

Department of Obstetrics and Gynecology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada rachelkim89@gmail.com eiriksson@HHSC.CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH